Literature DB >> 20404120

Effects of probiotics on acquisition and spread of multiresistant enterococci.

Marieke J A de Regt1, Rob J L Willems, Ronald J Hené, Peter D Siersema, Harald J J Verhaar, Titia E M Hopmans, Marc J M Bonten.   

Abstract

Ampicillin-resistant Enterococcus faecium (ARE) and vancomycin-resistant E. faecium (VRE) are important nosocomial pathogens. We quantified effects of probiotics and antibiotics on intestinal acquisition of ARE colonization in patients hospitalized in two non-intensive care unit (non-ICU) wards with high ARE prevalence. In a prospective cohort study with crossover design, all patients with a length of stay of >48 h were offered a multispecies probiotic product twice daily until discharge (4.5 months, intervention period) or not (4.5 months, control period). Perianal ARE carriage was determined <48 h after admission, twice weekly, and <48 h before discharge. The first isolates were genotyped by multiple-locus variable-number tandem repeat analysis (MLVA). Risk factors for acquisition were determined by Cox proportional hazards modeling, with special emphasis on ecological postantibiotic effects and delays between actual acquisition and culture positivity. Of 530 patients included, 94 (18%) were ARE colonized on admission. Of the remaining 436 noncolonized patients, 92 acquired ARE colonization: 28 (25%) of 110 probiotic users and 64 (20%) of 326 control patients (chi(2) test, P = 0.325). In all, 661 ARE strains were isolated from 186 patients, of which 186 were genotyped. In both wards, two MLVA types (MTs; MT1 and MT159) were responsible for >80% of acquisitions. Both MTs were genetically different from the probiotic E. faecium strain. Antibiotics to which ARE is resistant (hazard ratio [HR], 7.73 [95% confidence interval (CI), 4.52 to 13.22]), an ecological postantibiotic effect (HR, 7.11 [95% CI, 3.10 to 16.30]), and age (HR, 1.01 [95% CI, 0.99 to 1.02]) were associated with ARE acquisition. The HR of probiotics was 1.43 (95% CI, 0.88 to 2.34). In a setting with high selective antibiotic pressure, probiotics failed to prevent acquisition of multiresistant enterococci.

Entities:  

Mesh:

Year:  2010        PMID: 20404120      PMCID: PMC2897316          DOI: 10.1128/AAC.01765-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  21 in total

Review 1.  Vancomycin-resistant enterococcal infections.

Authors:  B E Murray
Journal:  N Engl J Med       Date:  2000-03-09       Impact factor: 91.245

Review 2.  Insights into the epidemiology and control of infection with vancomycin-resistant enterococci.

Authors:  M K Hayden
Journal:  Clin Infect Dis       Date:  2000-10-25       Impact factor: 9.079

Review 3.  Effects of antibiotics on nosocomial epidemiology of vancomycin-resistant enterococci.

Authors:  Stephan Harbarth; Sara Cosgrove; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

Review 4.  Time-dependent covariates in the Cox proportional-hazards regression model.

Authors:  L D Fisher; D Y Lin
Journal:  Annu Rev Public Health       Date:  1999       Impact factor: 21.981

5.  Effect of parenteral antibiotic administration on the establishment of colonization with vancomycin-resistant Enterococcus faecium in the mouse gastrointestinal tract.

Authors:  C J Donskey; J A Hanrahan; R A Hutton; L B Rice
Journal:  J Infect Dis       Date:  2000-05-15       Impact factor: 5.226

6.  The role of "colonization pressure" in the spread of vancomycin-resistant enterococci: an important infection control variable.

Authors:  M J Bonten; S Slaughter; A W Ambergen; M K Hayden; J van Voorhis; C Nathan; R A Weinstein
Journal:  Arch Intern Med       Date:  1998-05-25

Review 7.  Effect of antimicrobial agents on the ecological balance of human microflora.

Authors:  A Sullivan; C Edlund; C E Nord
Journal:  Lancet Infect Dis       Date:  2001-09       Impact factor: 25.071

8.  Reduction in acquisition of vancomycin-resistant enterococcus after enforcement of routine environmental cleaning measures.

Authors:  Mary K Hayden; Marc J M Bonten; Donald W Blom; Elizabeth A Lyle; David A M C van de Vijver; Robert A Weinstein
Journal:  Clin Infect Dis       Date:  2006-04-27       Impact factor: 9.079

9.  Increasing resistance to beta-lactam antibiotics among clinical isolates of Enterococcus faecium: a 22-year review at one institution.

Authors:  M L Grayson; G M Eliopoulos; C B Wennersten; K L Ruoff; P C De Girolami; M J Ferraro; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

10.  Biliary excretion of piperacillin.

Authors:  E W Taylor; V Poxon; J Alexander-Williams; D Jackson
Journal:  J Int Med Res       Date:  1983       Impact factor: 1.671

View more
  11 in total

1.  Enterococci and Their Interactions with the Intestinal Microbiome.

Authors:  Krista Dubin; Eric G Pamer
Journal:  Microbiol Spectr       Date:  2014-11

2.  Escherichia coli Probiotic Strain ED1a in Pigs Has a Limited Impact on the Gut Carriage of Extended-Spectrum-β-Lactamase-Producing E. coli.

Authors:  G Mourand; F Paboeuf; M A Fleury; E Jouy; S Bougeard; E Denamur; I Kempf
Journal:  Antimicrob Agents Chemother       Date:  2016-12-27       Impact factor: 5.191

3.  Randomized Controlled Trial to Determine the Impact of Probiotic Administration on Colonization With Multidrug-Resistant Organisms in Critically Ill Patients.

Authors:  Jennie H Kwon; Kerry M Bommarito; Kimberly A Reske; Sondra M Seiler; Tiffany Hink; Hilary M Babcock; Marin H Kollef; Victoria J Fraser; Carey-Ann D Burnham; Erik R Dubberke
Journal:  Infect Control Hosp Epidemiol       Date:  2015-08-27       Impact factor: 3.254

Review 4.  The Role of Probiotics, Prebiotics and Synbiotics in Combating Multidrug-Resistant Organisms.

Authors:  Alexander M Newman; Mehreen Arshad
Journal:  Clin Ther       Date:  2020-08-12       Impact factor: 3.393

5.  Changes in human fecal microbiota due to chemotherapy analyzed by TaqMan-PCR, 454 sequencing and PCR-DGGE fingerprinting.

Authors:  Jutta Zwielehner; Cornelia Lassl; Berit Hippe; Angelika Pointner; Olivier J Switzeny; Marlene Remely; Elvira Kitzweger; Reinhard Ruckser; Alexander G Haslberger
Journal:  PLoS One       Date:  2011-12-14       Impact factor: 3.240

6.  Public health evolutionary biology of antimicrobial resistance: priorities for intervention.

Authors:  Fernando Baquero; Val F Lanza; Rafael Cantón; Teresa M Coque
Journal:  Evol Appl       Date:  2014-12-11       Impact factor: 5.183

7.  Photodynamic and antibiotic therapy impair the pathogenesis of Enterococcus faecium in a whole animal insect model.

Authors:  José Chibebe Junior; Beth B Fuchs; Caetano P Sabino; Juliana C Junqueira; Antonio O C Jorge; Martha S Ribeiro; Michael S Gilmore; Louis B Rice; George P Tegos; Michael R Hamblin; Eleftherios Mylonakis
Journal:  PLoS One       Date:  2013-02-14       Impact factor: 3.240

Review 8.  Decolonization of gastrointestinal carriage of vancomycin-resistant Enterococcus faecium: case series and review of literature.

Authors:  Vincent C C Cheng; Jonathan H K Chen; Josepha W M Tai; Sally C Y Wong; Rosana W S Poon; Ivan F N Hung; Kelvin K W To; Jasper F W Chan; Pak-Leung Ho; Chung-Mau Lo; Kwok-Yung Yuen
Journal:  BMC Infect Dis       Date:  2014-09-23       Impact factor: 3.090

Review 9.  Impact of microbiome-based interventions on gastrointestinal pathogen colonization in the intensive care unit.

Authors:  Alexa Choy; Daniel E Freedberg
Journal:  Therap Adv Gastroenterol       Date:  2020-07-17       Impact factor: 4.409

10.  Proof-of-concept trial of the combination of lactitol with Bifidobacterium bifidum and Lactobacillus acidophilus for the eradication of intestinal OXA-48-producing Enterobacteriaceae.

Authors:  Juan Carlos Ramos-Ramos; Fernando Lázaro-Perona; José Ramón Arribas; Julio García-Rodríguez; Jesús Mingorance; Guillermo Ruiz-Carrascoso; Alberto M Borobia; José Ramón Paño-Pardo; Rafael Herruzo; Francisco Arnalich
Journal:  Gut Pathog       Date:  2020-04-07       Impact factor: 4.181

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.